Susvimo® (ranibizumab intravitreal injection via ocular implant)

When requesting Susvimo® (ranibizumab intravitreal injection via ocular implant), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines.

FDA-approved indication

Susvimo is indicated for the treatment of patients with Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor medication.

Coverage Guidelines

Due to safety concerns, approval is not recommended for Susvimo. There are significant risks of use based on the Boxed Warning regarding endophthalmitis.

References

1. Susvimo™ intravitreal injection via ocular implant [prescribing information]. South San Francisco, CA: Genentech/Roche; May 2025.